BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia

Leukemia

Volumn 27, Issue 7, 2013, Pages 1578-1580

  Agatheeswaran, S ^a   Singh, S ^a   Biswas, S ^b   Biswas, G ^b   Chandra Pattnayak, N ^c   Chakraborty, S ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

^b Department of Medical Oncology   (India)

^c SCB MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MICRORNA 223;

ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; BONE MARROW MONONUCLEAR CELL; CANCER PATIENT; CELL ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MEDIATOR; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MADS DOMAIN PROTEINS; MICRORNAS; MYOGENIC REGULATORY FACTORS; NERVE TISSUE PROTEINS; POLYPYRIMIDINE TRACT-BINDING PROTEIN;

EID: 84880260054     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.339     Document Type: Article

References (15)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Flamant S, Richie W, Guilhot J, Hols J, Bonnet ML, Chomel JC et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 2010; 95: 1325-1333.
3. Agirre X, Velasco A, San José-Ené riz E, Garate L, Bandré s E, Cordeu L et al. Downregulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res 2008; 6: 1830-1840.
4. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010; 140: 652-665.
5. Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y et al. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell 2007; 129: 617-631.
6. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005; 123: 819-831.
7. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K et al. BCR-ABL suppresses C/EBP alpha expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30: 48-58.
8. Pulikkan JA, Dengler V, Peramangalam PS, Zada AAP, Muller-Tidow C, Bohlander SK et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 2010; 115: 1768-1778.
9. Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 2007; 12: 457-466.
10. Baek D, Villén C, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008; 455: 64-71.
11. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
12. Stehling-Sun S, Dade J, Nutt SL, DeKoter RP, Camargo FD. Regulation of lymphoid versus myeloid fate 'choice' by the transcription factor Mef2c. Nat Immunol 2009; 10: 289-296.
13. Xue Y, Zhou Y, Wu T, Zhu T, Ji X, Kwon Y et al. Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell 2009; 36: 996-1006.
14. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86.
15. Salesse S, Dylla SJ, Verfaillie CM. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells. Leukemia 2004; 18: 727-733.